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1. Introduction 
The outcome of lung cancer has not changed dramatically in recent years, despite the 
availability of new therapeutic agents. Lung cancer is the most common cause of cancer-
related death in all industrialised countries (28 % in the USA for 2009). It is usually treated 
by a combination of surgery, radiotherapy and chemotherapy; and anticancer drugs are 
generally given intravenously. But this delivery route leads to high drug concentrations in 
the systemic circulation, with some adverse side effects and low drug concentrations in the 
respiratory tract. Clearly, a new route for administering anti-cancer drugs is needed: the 
airways. Drugs for treating chronic respiratory diseases like asthma, chronic obstructive 
pulmonary disease (COPD) and cystic fibrosis are commonly delivered via the airways. The 
main advantage of this route is that the drug is delivered directly into the bronchi, 
bronchioles or deep lungs. Airway delivery should theoretically ensure longer exposure of 
the intended target to higher concentrations of the drug, while reducing adverse side effects. 
The patient should therefore benefit from a minimum drug concentration in the 
bloodstream and other body tissues. The airways therefore appear to be an attractive route 
for delivering anticancer agents in lung cancer, especially when other treatments have 
limited success, and in particular pathological situations, such as bronchioloalveolar 
carcinoma (BAC). This chapter provides an overview of the delivery of anticancer agents by 
aerosoltherapy for treating lung cancers and metastases, including the current status in the 
use of aerosoltherapy in oncology and future progress. 
2. Challenge of aerosol drug delivery in lung cancer 
2.1 Aerosol deposition 
Effective drug delivery to the lungs via the airways requires a detailed knowledge of 
aerosols. The main parameters that should be considered are the particle size, the 
inspiratory flow rate, the volume of the inhalation and the calibre of the patient’s airways. 
The model developed by Weibel divides the lungs into 23 serial branching generations. The 
first sixteen form the conducting bronchial airways and the last seven, the respiratory zone 
(or alveolar region) (Weibel et al., 1963). The lungs may also be divided in three parts, upper 
(apex), middle and lower (base). Thus the major challenge involved in delivering drugs into 
the lungs is provided by the complex structure of the respiratory tract.  
www.intechopen.com
 Advances in Cancer Therapy 
 
54
Aerosols generally have a polydisperse particle size distribution, and particle size is one of 
the most important factors influencing aerosol deposition in the lungs. The mass median 
aerodynamic diameter (MMAD) is usually used to estimate the particle size distribution. 
The MMAD describes an aerosol in terms of its mass and size. It is defined as 50 % of the 
mass of the particles less than MMAD and 50 % greater than the MMAD (Soderlom, 1989). 
Analysis of lung depositions indicated that almost all particles with a MMAD >5 µm are 
deposited in the oropharynx. Most of those with a MMAD of 2 to 6 µm are deposited in the 
bronchi (conducting airways) and fine particles with a MMAD <2 µm are deposited in the 
alveolar region. Most of the particles smaller than 1 µm are presumably exhaled (Newman 
et al., 1983). 
The depositing of particles in the lungs also depends on several other parameters. One is the 
inspiratory flow rate (IFR). The particles display high velocity and turbulence when the IFR 
increases, causing them to be deposited in the conducting airways (Dolovich et al., 2000). 
Thus drug deposition in the upper airways can be improved by increasing the IFR. In 
contrast, a low IFR and gas density help aerosols to penetrate into the lung periphery 
(Anderson et al., 1990). The penetration of particles into the alveolar region also depends on 
the inhaled volume. Particles are better deposited in the lung peripheries of patients with a 
high FEV1 (forced expiratory volume in one second) (Pavia et al. 1976). Similarly, rapid 
exhalation following a short breath hold can influence particle deposition in the large 
airway. The calibre of the airways also modulates particle deposition. There is excessive 
mucus secretion and accumulation in some respiratory diseases, such as cystic fibrosis and 
certain tumours, which leads to obstruction of the airways. This reduction in airway calibre 
has a negative influence on the deposition and distribution patterns of aerosols. Particle 
deposition is dramatically decreased in cystic fibrosis patients, even from aerosols with fine 
particles (<2µm), because of the secretions and reduced airway calibre (Dolovich, 2009). 
The diameter of the airways of children is much smaller than those of adults. Hence, 
particles are deposited mainly in the oropharynx or upper airways because they impact 
rapidly on the bronchus barrier. The breathing patterns of children also differ from those of 
adults. Their tidal volume is smaller (volume of air displaced between normal inspiration 
and expiration) and their respiratory rate higher than those of adults, which prevents drugs 
from being deposited in the alveolar region. Co-operation and compliance complicate the 
administration of drug to children via the airways. Cries can be assimilated to a rapid 
exhalation, leading to deposition of drug almost exclusively on the surface of the 
oropharynx (Schüepp et al., 2004). 
Few studies focused on the deposition of inhaled particles in the lungs of the elderly. They 
have shown that the particle deposition in old and younger patients with lung diseases were 
similar. However, some pulmonary delivery devices are unsuitable for patients suffering 
from memory loss and disorders of movement coordination (Allen et al., 2008). 
2.2 Technology of delivery devices 
Several devices have been developed to generate aerosol particles. They include nebulisers, 
pressurized-metered dose inhalers (pMDI) and dry powder inhalers (DPI). Nebulisers are 
widely used for drug inhalation, and there are three types of nebuliser: pneumatic (or jet), 
ultrasonic and vibrating-mesh. Pneumatic nebulisers use compressed air to aerosolise drug 
solutions. These solutions are carried into the gas stream and dispersed into droplets due to 
surface tension (Hess et al., 2008). A fill volume of 4-5 ml is optimal and normal saline is 
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added when the volume is lower. Ultrasonic nebulisers use a high-frequency piezoelectric 
system to produce ultrasound, which then nebulises a drug solution. This system is not 
compatible with all molecules because the ultrasound can destroy certain drugs. In 
vibrating-mesh nebulisers, the drug solution is compressed by perforated membranes that 
are vibrating rapidly. All types of nebuliser are only half as efficient with nasal inhalation as 
with oral inhalation (Everard et al., 1993). 
A pMDI is a handheld device that contains a drug in solution or suspension and a gas like 
hydrofluoroalkane to propel the solution/suspension. It must be shaken before use to mix 
gas with the drug solution/suspension. The most important component of the pMDI is the 
metering valve (Hess et al., 2008). This is because the pMDI canister is used inverted, and 
the valve prevents the drug from leaking due to gravity. The advantages of this system are 
its small size, ease of use, and its portability. However, good coordination between hand 
movements and inhalation is needed for efficient drug deposition. Devices with an 
automatic release have been developed for patients with coordination disorders. A valve 
holding chamber can also be placed between the MDI and the patient to ensure that aerosol 
is retained in the chamber and released when the patient breathes. 
The drug used in the DPI system is formulated as a dry powder. The devise has a dosing 
principle and an inhaler (Pedersen, 1996). The powder is broken down into small particles 
by the force of the patient’s inhalation. DPI is available in multi-dose and single-dose 
models. The single-dose model has a single drug capsule that must be manually inserted 
into the device by the patient. These drug capsules must not be ingested. 
Education is essential for effective drug delivery via the airways. Nurses, physicians and 
pharmacists must all learn how to use inhalers so as to prevent their misuse or inadequate 
treatment. Mishandling of aerosol devices like the pMDI is associated with decreased 
asthma control (Giraud and Roche, 2002). Patients must be also educated to inhale properly 
in order to maximize drug deposition in the intended lung compartment. Most of the 
anticancer drugs presently being evaluated in clinical trials have been administered to the 
airways with nebulisers. Nebulisers and endotracheal sprays have generally been used to 
deliver anticancer drugs in preclinical studies to animals. 
2.3 Recommendations for delivering anticancer drugs via the airways 
Official sources, such as the European Respiratory Society, have not yet established 
procedures for using anticancer drugs to treat lung cancer. They have only discussed the 
lack of evidence for using opiates and bronchodilators in palliative care (Boe et al., 2001). 
Herein, we propose some advices based on official recommendations established for other 
respiratory diseases (such as COPD and asthma). Certain steps should be scrupulously 
respected if a drug is administered via the airways. The choice of the device is critical 
because they are not compatible for all drugs. Physicians may prefer not to use pMDI or DPI 
systems for patients with coordination disorders or memory deficiency. A mouthpiece is the 
most suitable means of improving lung deposition and is safer for the patient as it avoids 
injuring the eyes. The manufacturer’s instructions (formulation, solution volume and type of 
driver gas) should be respected to ensure optimal drug deposition, and effective treatment. 
Nebulisers should be cleaned carefully to prevent bacterial contamination and subsequent 
lung infections. Maintenance procedures are available for all nebulisers and they should be 
communicated to the patient. Single-dose nebulisers may be most suitable for hospitalised 
patients, with replacement every 24 hours.  
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Great care should be taken when administering anticancer agent via the pulmonary route. 
Anticancer agents are potentially toxic for the lung and may impair the pulmonary function 
in some patients, but most of them are not very toxic when the inhalation procedure is 
standardized and the dose well defined. The safety of healthcare workers should be 
considered. Aerosolised chemotherapy should be delivered in a well-ventilated room with 
an efficient air filtering system (Gagnadoux et al., 2007). Wittgen et al demonstrated the 
advantages of combining a mobile HEPA (High Efficiency Particulate Air) filter air cleaning 
system with a demistifier tent to prevent aerosol propagation during inhalation of nebulised 
liposomal cisplatin (Wittgen et al., 2006). 
3. Aerosolisation of anticancer agents 
3.1 Formulation of anticancer drugs for aerosol delivery 
Particle size is one of the most critical parameters for ensuring efficient drug deposition in 
the respiratory tract. Several parameters influence drug targeting to the desired lung area: 
these are the size, shape, density, electrical charge and hygroscopicity of the aerosol particles 
(Pilcer and Amighi, 2010). It is also essential that the aerosolised drug remains 
pharmacologically active. Formulations for nebulised drug traditionally include sodium 
chloride or other salts to adjust the osmolarity, HCl or NaOH to obtain a stabilised neutral 
pH and a surfactant such as polysorbates to avoid drug aggregates. But other methods have 
been developed to produce particles with controlled properties; these include jet milling, 
spray drying and supercritical fluid techniques. Excipients like lipids and polymers are also 
used to improve pulmonary deposition (Pilcer and Amighi, 2010).  
Some drugs are encapsulated into liposome to increase their resident time into the lungs 
(Cryan, 2005). Liposomal formulations generally provide sustained drug release, prevent 
local irritation, and improve drug stability. For example, the resident time in the lungs of 
liposomal cyclosporine A is nearly 17 times longer than that of the standard compound 
(Arppe et al., 1998). The lipids most commonly used to produce liposome are lecithins 
(phosphatidylcholines), phosphatidylethanolamines, phosphatidylserines, and 
phosphatidylinositols. Formulations with microspheres have also been developed. 
Although, they are mostly used to deliver drugs whose intended actions are systemic, such 
as vaccines and insulin, more and more formulations of anticancer agents associated with 
microspheres are being developed. Microspheres are produced using natural or synthetic 
polymers. The two most commonly used synthetic polymers are polylactic acid (PLA) and 
polylacticco-glycolic acid (PLGA) (Cryan, 2005). The rate at which a drug is released from 
microparticles depends on its dissolution and diffusion. 
New formulations are today developed for the controlled release of the drug and to enhance 
anticancer efficacy. Biotinylated-EGF-modified gelatine was tested as a carrier for cisplatin 
with better anticancer and less toxic effect than free cisplatin after aerosolisation in vitro and 
in vivo (Tseng et al., 2009). Encapsulation of anticancer agent in nanoparticles is also 
evaluated, in particular through airways delivery with some promising results (El-Gendy 
and Berckland, 2009, Hureaux et al., 2009, Tomoda et al., 2009). 
3.2 Pharmacological properties of aerosolised anticancer agents 
Most anticancer drugs resist the physical constraints of aerosolisation, retain their 
pharmacological properties, and produce particles with aerodynamic properties that are 
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compatible with lung deposition. A study by Gagnadoux et al. showed that the cytotoxicity of 
a nebulised formulation of the nucleoside analog gemcitabine (GCB) was similar to that of the 
native drug when tested against NCI-H460 and A549 Non-Small Cell Lung Cancer (NSCLC) 
cells  (Gagnadoux et al., 2006). Another study of the cytotoxicity of a nebulised farnesol 
formulation containing polysorbate 80 (Tween 80) in vitro for NSCLC lines (H460 and A549) 
showed that the anticancer properties of nebulised farnesol were essentially the same as those 
of the native drug (Wang et al., 2003). The cytotoxic effects of doxorubicin before and after 
encapsulation were compared in vitro using growth inhibition assays. Azarmi et al. (2006) 
studied doxorubicin (DOX)-loaded nanoparticles formulated as a dry powder by spray-freeze-
drying. The cytotoxic effects of free DOX, carrier particles containing blank nanoparticles and 
DOX-loaded nanoparticles were assessed using H460 and A549 lung cancer cells. The DOX-
nanoparticles were more cytotoxic for both cell lines a higher than were the blank 
nanoparticles and the free DOX. The aerosolisation of therapeutic proteins such as anticancer 
antibodies has also been tested. The results showed that some inhalers are suitable for limiting 
the formation of aggregates and preserving the pharmacological activity of the antibody in 
vitro (Maillet et al., 2008). Cetuximab, a chimeric IgG1 that targets the epidermal growth factor 
receptor (EGFR), was tested with three types of nebulisers: jet, mesh and ultrasonic. The 
immunological and pharmacological properties of nebulised cetuximab were evaluated using 
A431 cells. Flow cytometric analyses and assays of EGFR-phosphorylation and the inhibitions 
of A431 cell growth demonstrated that the mesh and jet nebulisers did not destroy the ability 
of cetuximab to bind to EGFR or its inhibitory activity. 
4. Airways delivery in preclinical studies 
4.1 Animal models for aerosol delivery in cancer 
4.1.1 Animal model for assessing lung deposition 
The structure of the human nasal system is very different from that of all other animals 
except the non-human primates. The nasal anatomy of primates (human and non-human) is 
much simpler than that of the majority of animals (Gross et al., 1991.). Rodents cannot 
breathe through their mouths. Particles must be smaller than 3 µm if they are to reach the 
airways of rodents (Miller et al., 2000). One way to avoid nasal deposition is to introduce a 
catheter connected to a high pressure syringe into the trachea to deliver aerosols directly 
into the lungs. There are two types of tracheo-bronchial anatomy, dichotomous division and 
monopodial division (McBride et al. 1991). The human respiratory tract is considered to 
undergo dichotomous branching, while those of rats, mice and dogs are monopodial. This 
anatomical difference does not seem to influence aerosol deposition in the lungs, but further 
studies are needed to confirm this. The transition between bronchial airways and the 
alveolar region is gradual in humans; humans have respiratory bronchioles, while rodents 
do not (Tyler et al., 1993). Inhaled particles are cleared faster from the alveoli of rodents than 
from the alveoli of humans because rodents lack bronchioles. However, additional studies 
are required to determine whether this difference influences the deposition of aerosolised 
particles in the lungs (Phalen et al., 2008). Total aerosol deposition is better in nasal 
breathing humans than in oral breathing humans. Upper respiratory tract deposition is 
similar in nasal breathing humans and in dogs, hamsters, and rabbits. However, pulmonary 
deposition in nasal breathing humans is comparable to that of dogs and monkeys, but lower 
than in hamsters and rats. The peak particle size for pulmonary deposition is larger in 
humans than in dogs, guinea pigs, monkeys, and rats (Phalen et al., 2008) 
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4.1.2 Animal models for anticancer drug studies 
4.1.2.1 Chemically induced lung cancer 
Several animal models of lung cancer have been developed and used to understand 
carcinogenesis and test anticancer agents. One of them is chemically-induced lung cancer. 
These animal models are usually used only to study carcinogenesis and cancer prevention 
because of the long time required for tumour development and the poor therapeutic 
response. Newborn A/J mice injected intraperitoneally with ethyl carbamate (urethane) 
begin to develop benign lung adenomas within few months, followed by degenerate 
adenocarcinomas similar to those of humans (Shimkin et al., 1975). Some of the many 
chemical agents that have been tested for their ability to induce lung tumours and study 
carcinogenesis are benzopyrene, metals, aflatoxin, and constituents of tobacco smoke such 
as polyaromatic hydrocarbons and nitrosamines (Liu et al., 2002). But chemical models have 
rarely been used in aerosol studies except for aerosolised chemopreventive treatment. 
4.1.2.2 Transgenic lung cancer 
Transgenic mouse models of lung adenocarcinoma expressing a mutant active K-ras 
transgene are available. Jonhson et al. (2001) created a mouse strain (K-ras LA1) carrying an 
oncogenic allele of K-ras that had an activating codon 12 mutation (gly to asp) on exon 1, 
that can be activated only on a spontaneous recombination event in the whole animal 
(Jonhson et al., 2001). This mutation, probably in combination with other somatically 
acquired mutations, leads to the development of multifocal lung adenocarcinomas in 100% 
of the mice, skin papillomas in 23%, and thymic lymphomas in 35%. Lung tumours can first 
be detected microscopically when the mice are 2 weeks old, and the number and size of 
tumours increase continuously until they essentially fill the thoracic cavity, causing the 
mouse to die of respiratory failure (mean survival 300 days). Extrathoracic metastases are 
rare and occur only at a very late stage of the disease, as in humans with adenocarcinoma 
(Wislez et al., 2003; Jonhson et al., 2001). The radiological appearance is also very similar to 
the human disease with multifocal lesions such as nodules with ground glass attenuation 
(Cody et al., 2005). We are presently using this model to analyze the administration of 
anticancer drugs via the airways. 
4.1.2.3 Human lung tumour xenografts  
Human lung tumour xenografts are widely used in cancer therapeutic studies. Nude mice 
or SCID immunosuppressed mice are injected intravenously or into the lungs with human 
tumour cells. Orthotopic models of lung cancer have also been evaluated for aerosol studies. 
Lung cancer cells, mainly H460 (large cell lung carcinoma) and A549 (bronchioloalveolar 
lung carcinoma) or disaggregated lung tumours are implanted endotracheally in 
immunocompromised mice. Orthotopic models are interesting because the tumours grow 
directly into the lungs, in an environment mimicking that of human lung neoplastic cells. 
Models of pulmonary metastases have also been used in aerosol studies. For example, LM7 
and LM8 osteosarcoma cells were injected intravenously into immunosuppressed mice, 
leading to the development of lung metastases (Koshkina and Kleinerman, 2005). Lastly, 
tumours grow better in the lungs than in the subcutaneous compartment. The cell lines most 
frequently used in animal studies are H460 (large cell lung carcinoma) and A549 (lung 
carcinoma). 
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4.2 Pharmacokinetics of anticancer agents delivered via the airways in animals 
4.2.1 Lung deposition 
The concentrations in the lungs of anticancer drugs delivered by the pulmonary route are 
higher than the concentrations delivered by any other route. Cisplatin, one of the major 
drugs used to treat lung cancers, is administered systemically. Delivery of cisplatin via a 
catheter placed in right caudal lung lobe in dogs provided a concentration in the right 
caudal lobe that was 44 times higher than in other pulmonary lobes (Selting et al., 2008). The 
pulmonary delivery of other anticancer drugs that are clinically injected intravenously, but 
are unconventional for treating non small cell lung cancer, was also tested. The deposition of 
aerosolised liposomal camptothecin, a quinoline alkaloid, in the lungs was assessed in nude 
mice with colon, breast or lung tumour xenografts. The concentration of the encapsulated 
camptothecin in the lung was 100 times higher following airways administration than after 
intramuscular injection (Koshkina et al., 1999). Similarly, the concentration of aeorosolised 5-
Fluorouracile (5-FU) in the lung tissue was 1000 times higher than in the serum of hamsters 
(Hitzman et al., 2006). High concentrations of 5-FU were detected in the trachea and bronchi 
of dogs after airways delivery, whereas a lower concentration was measured in the 
peripheral lung (Tatsumura et al., 1993). We have used near infrared imaging to analyze the 
distribution of cetuximab, an anti-EGFR antibody, in a xenograft model of lung tumour 
following systemic and pulmonary delivery, (Maillet et al., in press). The antibody 
accumulated rapidly and durably in the lungs (Figure 1), and the lung concentration was 
higher following airways delivery (not shown) (Maillet et al., in press). 
 
      
A B C D E  
Fig. 1. Lung deposition of inhaled cetuximab at (A) 1h30 (B) 8h (C) 24h (D) 48h and (E) 72h.  
4.2.2 Blood passage 
Most studies have shown that the concentration of an anticancer drug in the bloodstream is 
lower after airways delivery than after systemic injection. For example, the concentration of 
cisplatin in the serum was 15.6 times lower after pulmonary administration than after 
intravenous (i.v.) injection (Selting et al., 2008). Gemcitabine was given to 3 baboons via the 
airways and its concentration in the blood was 25 times lower than after its systemic 
delivery (Gagnadoux et al., 2006). Dogs with spontaneous pulmonary metastases were given 
aerosolized paclitaxel and doxorubicin and the drug concentrations in the bloodstream were 
measured 1 minute later (Hershey et al., 1999). The serum concentrations were lower than 
when the drugs were delivered intravenously. However a pharmacokinetic analysis is 
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required to support this conclusion. We have recently determined the pharmacokinetics of 
cetuximab delivered systemically and via the lungs.  Little cetuximab was found in the 
bloodstream after airways delivery (only 11% of the fraction delivered to the lungs) and its 
passage was slow with a peak around 48 hours (Maillet et al., in press). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Serum concentrations of cetuximab delivered systemically or via the pulmonary 
route.  
4.3 Efficacy and safety of anticancer agents delivered via the airways in animals 
4.3.1 Cisplatin 
Selting and co-workers aerosolised cisplatin directly into the right caudal lobes of healthy 
dogs (Selting et al., 2008). They found no haematological toxicity and this delivery of 
aerosolised cisplatin was generally very well tolerated. Radiological and histological 
analyses indicated that all the dogs developed mild to moderate pneumonitis in the right 
caudal lobe where the drug was delivered. Chemotherapy with both cisplatin and 
gemcitabine was also delivered through the pulmonary route in healthy dogs using the 
same method (Selting et al., 2011). As previously reported, the only adverse event observed 
was focal pneumonitis in the right caudal lung lobe. Overall, the local-regional delivery of 
cisplatin either alone or in combination was well tolerated, suggesting that aerosolised 
platin-based chemotherapy may be used safely to treat humans. However, this method may 
be difficult to administer to patients with chronic respiratory failure. 
4.3.2 Paclitaxel 
Dogs with spontaneous primary or secondary lung tumours were given aerosolised 
paclitaxel using a jet nebuliser (Hershey et al., 1999). One of the 15 dogs had a partial 
response and one had a complete response with long term survival. The thirteen remaining 
had stabilised or progressive disease. In another study, mice with pulmonary metastases 
were given paclitaxel encapsulated in liposomes using a pneumatic nebuliser (Koshkina et 
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al., 2001). There were significantly fewer tumours in the treated mice than in the mice given 
liposome alone. Survival was improved, with 40% of the mice treated with liposomal 
paclitaxel being alive after 45 days, whereas all the mice treated with liposome alone were 
dead. A recent study found that adding vitamin E to the aerosolised liposomal-encapsulated 
paclitaxel enhanced the anticancer response to paclitaxel in murine model of lung 
metastases from primary breast cancer (Latimer et al. 2009). Lastly, the feasibility of 
aerosolising paclitaxel encapsulated in lipid nanoparticles was tested in vitro. Preclinical 
studies in animal models of lung cancer are expected to evaluate whether encapsulation 
leads to the controlled release of the drug (Hureaux et al., 2009). 
4.3.3 Gemcitabine 
Gagnadoux et al. evaluated the dose-limiting toxicity of gemcitabine delivered 
endotracheally to Wistar rats with a sprayer (Gagnadoux et al., 2005). The maximum 
tolerated dose was 4 mg/kg. They detected no toxicity, except for decreases in platelet and 
red blood cell counts, when gemcitabine had been inhaled once a week for 9 weeks. They 
also evaluated the antitumor efficacy of aerosolised gemcitabine in nude mice implanted 
intrabronchially with H460 cells (Gagnadoux et al., 2005). Of the 13 mice given aerosolised 
gemcitabine, 4 had no visible tumour at the end of the experiment. And those tumours 
remaining in the treated mice were smaller (2.05 mm) than those in the control group (5 
mm). Aerosolised gemcitabine also significantly reduced tumour numbers in a pulmonary 
metastases murine model of osteosarcoma (Koshkina et al., 2005). Also, dogs with 
spontaneous lung metastases of osteosarcoma were treated in a preclinical study with 
aerosolised gemcitabine combined with a standard treatment regimen (Rodriguez et al., 
2010). Almost half (46%) of the treated dogs showed over 50% tumour necrosis, but there 
was no necrosis in the untreated animals.  
4.3.4 Doxorubicine 
Hershey et al. treated 18 dogs with spontaneous primary or secondary lung tumours with 
aerosolised doxorubicine using a jet nebuliser (Hershey et al., 1999). There were 4 partial 
responses and treatment was well tolerated except for some coughing by half of the subjects, 
cardiotoxicity in two animals, and mild to moderate pneumonitis in almost all the dogs. 
4.3.5 Camptothecin 
Aerosolised liposomal 9-nitro-20(S)-camptothecin (L9-NC) was first assessed in mice with 
xenografts of breast, colon and lung tumours injected subcutaneously (Knight et al., 1999). 
Treatment started 1 to 4 weeks after tumour implantation and was given 5 days a week. The 
growth of subcutaneous tumours was 7- fold lower in treated animals with breast cancer 
than in the controls and 7 to 10-fold lower in the mice with colon cancers. The lung tumour 
xenografts were also smaller in the mice treated with aerosolised L9-NC than in the controls. 
The antitumor effect of L9-NC was better when it was delivered through the airways than 
orally in all the systems. L9-NC was also evaluated in nude mice with lung metastases 
produced by the i.v. injection of melanoma (B16) or osteosarcoma (LM6) cells (Koshkina et 
al., 2000). The mice were given aerosolized L9-NC 5 days a week for three weeks. The 
treated mice with lung metastases of melanoma had statistically smaller (mean diameter 32 
mm) tumour foci than the control group (85 mm). Similarly, 10 of the 11 control mice with 
LM6 lung metastase, had visible tumours, whereas none of 11 treated mice had tumours, 
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suggesting that these tumors were very sensitive to aerosolised L9-NC. Gilbert et al. 
evaluated the safety of aerosolised L9-NC in healthy dogs. They found no toxicity after 
treatment with this drug for 5 days a week for 8 weeks (Gilbert et al., 2002). 
4.3.6 Temozolomide 
Wauthoz and co-workers evaluated aerosolised temozolomide, a recent alkylating agent, in 
mice with pulmonary metastases obtained by injecting B16 melanoma cells i.v. (Wauthoz et 
al., 2010). The treatment seemed to be very well tolerated because the maximum tolerated 
dose was not reached. The antitumor activity of temozolomide was similar whether it was 
delivered through the airways or intravenously and both routes gave significantly better 
results than the control group. And three of the mice were long-term survivors. These 
encouraging results might lead to clinical trials. 
4.3.7 Interleukin-2 (IL-2) 
IL-2 is a cytokine that induces an antitumor immune response. Anderson et al. evaluated 
immunotherapy with aerosolised IL-2 using mice with pulmonary metastases of sarcoma 
(Anderson et al., 1990).  The antitumor activity of IL-2 delivered via the airways appeared to 
be better than via the other routes tested. Aerosolisation of IL-2 encapsulated in liposomes 
gave better survival than free IL-2 or liposome alone delivered via the same route. Tumour 
size was reduced by 50% to 85% by aerosolised liposomal IL-2, which was better than the 
results with free IL-2. This suggested that liposomal IL-2 was better than free IL-2.  
The efficacy of airways delivery of free IL-2 and liposomal IL-2 were also compared in 
healthy dogs (Khanna et al. 1996). There were increases in white cells and effector cells in 
the broncho-alveolar lavage fluid of dogs treated with liposomal IL-2 but no haematological 
or clinical toxicity. A preclinical study in which dogs were treated with aerosols of 
liposomal IL-2 gave spectacular results (Khanna et al., 1997). Aerosolised liposomal IL-2 was 
used to treat 9 dogs, 7 with pulmonary metastases of a primary osteosarcoma and 2 with 
primary lung carcinomas. The pulmonary nodules in 2 of the 4 dogs with metastatic 
pulmonary osteosarcomas were in complete regression. No relapse was observed over 12 
and 20 months, respectively. The disease of one of the two dogs with a primary lung 
carcinoma was stabilized for up to 8 months. Aerosolised IL-2 was widely evaluated in 
clinical trials to treat pulmonary metastases of renal cell carcinoma but there are few 
published preclinical studies in animals with IL-2 delivered via the pulmonary route. 
Clinical trials were probably proposed based on results obtained with IL-2 administered i.v. 
(Rosenberg et al., 1994) 
4.3.8 Celecoxib 
Celecoxib is a non-steroidal anti-inflammatory drug that inhibits cyclooxygenase 2. 
Treatment with aerosolised celecoxib was assessed in association with intravenous docetaxel 
in an orthotopic lung tumour model (A549) (Fulzele et al., 2006). Animals were given 
aerosolised celecoxib plus i.v docetaxel or oral celecoxib plus i.v. docetaxel, each of the 
drugs alone or a placebo. The aerosol was produced with a pneumatic nebuliser. 
Aerosolised celecoxib plus i.v. docetaxel reduced lung tumour volume by 61% compared to 
the placebo group while oral celecoxib plus i.v. docetaxel reduced it by 54%. Moreover, the 
combined treatments gave better results than the drugs alone. 
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4.3.9 Monoclonal antibodies 
We have recently evaluated the antitumor activity of aerosolised cetuximab in a xenograft 
model of lung tumours. Aerosolised cetuximab limited the growth of the lung tumours 
(Maillet et al., in press). This proof-of-concept study demonstrates that the airways can be 
suitable for delivering aerosolised monoclonal antibodies to treat lung cancer, but further 
studies are required to determine whether the pulmonary route really does increase the 
therapeutic benefit of monoclonal antibodies to patients with lung cancer. 
5. Airways delivery of anticancer agents in clinical studies 
5.1 Aerosolisation of anticancer drugs in primary lung cancer 
5.1.1 Cisplatin 
Cisplatin is the standard drug for treating non small cell lung cancers. It is given combined 
with another chemotherapeutic agent. Aerosolised cisplatin was assessed in a phase I study 
on 17 patients with lung cancer, including 16 with non-small-cell-lung cancer and one with 
small cell lung cancer (Wittgen et al., 2007). The cancers were progressing despite all 
previous treatment. Increasing doses of cisplatin encapsulated in liposomes were given. 
Each aerosol treatment was for 20 minutes with a jet nebuliser. The particles produced had a 
MMAD of about 3 µm. Each patient was given cisplatin on 1 to 4 consecutive days over a 
period of 21 days. The initial dose was 24 mg/m², which was doubled to 48 mg/m² without 
toxicity. The cycle was then shortened from 3 to 2 weeks, and finally to 1 week. Nebulised 
cisplatin was administered 3 times a day instead of twice. No dose-limiting toxicity was 
observed and the maximum tolerated dose was not reached. Dyspnea was reported in 11 
patients and a productive and irritating cough in 5. Eosinophilia was observed in 4 of these 
11 (36.4%) patients. Cisplatin was detected in the blood of only 4 patients. The disease of 12 
of the 17 patients became stable and it progressed in five of them, but the study was not 
constructed to assess the response to treatment. The dose-limiting toxicity was not reached, 
precluding a phase II study. 
5.1.2 Doxorubicin 
5.1.2.1 Safety and pharmacokinetic data 
Anthracycline is usually administered intravenously to treat various cancers, including 
small cell lung cancer. The most severe adverse response is cardiac toxicity. Delivering the 
drug by inhalation is an interesting alternative route which may limit the cardiac toxicity. A 
phase I study was conducted by Otterson et al. to assess the safety of inhaled doxorubicin 
(Otterson et al., 2007). The 53 patients taking part included 16 patients with a primary lung 
tumour without histology details. The remaining 37 had pulmonary metastases of sarcoma 
(n=19), osteosarcoma (n=6), colorectal (n=4), thyroid (n=3) and other primary tumours 
(n=5). They were given doxorubicin with a pneumatic nebuliser fitted with a device that 
captured any fugitive aerosol to protect health worker. The starting dose was 0.4 mg/m². 
Inhalation was given every 3 weeks. The majority of adverse events were pulmonary with 
cough (n=27), dyspnea (n=9), chest pain (n=5), wheezing (n=4), hoarseness (n=3), 
hemoptysis (n=1), and bronchospasm (n = 1). While 5 patients suffered grade 3-4 pulmonary 
toxicity such as hypoxemia or decreased lung function tests, it was difficult to differentiate 
the adverse effects of treatment and the consequences of the pulmonary disease. Two 
patients suffered severe toxicity in response to a dose of 9.4 mg/m², with respiratory 
distress in 1 patient and bilateral ground glass infiltrates in the other. The lung function tests 
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of the whole population were relatively stable and there was little non-pulmonary toxicity. 
There was no evidence of hematological toxicity. The authors concluded that the 
recommended dose for a phase II study is 7.5 mg/m². The maximal concentration (Cmax) of 
doxorubicin in the blood was low when the dose was less than 3 mg/m². Cmax increased 1.6 
times with doses of 3.8 - 7.5 mg/m². Cmax was more than doubled with doses of from 7.5 to 
9.4 mg/m². The maximal doxorubicin peak in the blood occurred within 5 minutes. This was 
due to its rapid passage through the alveolar-capillary barrier because doxorubicin is small 
and lipophilic.  
One patient with spindle cell sarcoma gave a partial response, while the diseases of 8 
patients were stable after 5 courses: 2 with bronchoalveolar carcinoma, 2 with soft tissue 
sarcoma, 1 with endometrial carcinoma, and 3 with thyroid cancer. The diseases of 6 
patients became stable after three courses. Two patients stopped treatment after first 
administration. The diseases of the remaining patients progressed. 
Very little inhaled doxorubicin enters the blood and probably has little systemic toxicity. It is 
difficult to come to any conclusion about treatment efficacy because the study was not 
constructed to do so, and the histological subtypes of cancers varied greatly. However, the 
stabilized bronchioalveolar carcinoma cases suggest that this histological pattern might be 
suitable for inhalation treatment with doxorubicin. 
5.1.2.2 Efficacy data 
Inhaled doxorubicin associated with systemic cisplatin and docetaxel at 75 mg/m² was 
tested in a phase I/II study on chemo-naive patients with advanced NSCLC (Otterson et al., 
2010). Among the 36 patients included in the study, 28 were given dose 1 (6 mg/m²) and 8 
were given dose 2 (7.5 mg/m²). The diffusing capacity of the lung for carbon monoxide 
(DLCO) of two of the patients given 7.5 mg/m² decreased and the recommended dose for 
the phase II study was 6 mg/m². The 34 patients in the phase II study, included 16 (47.1%) 
with adenocarcinoma, 5 (14.7%) with squamous cell carcinoma, 1 (2.9%), with large cell 
carcinoma, 11 (32.4%) with unspecified histology and 1 (2.9%) with a mixed tumour 
(squamous and adenocarcinoma). The patients were given 1 to 8 treatment cycles. Seven 
patients were given only one cycle and left the study because their disease progressed (n=3), 
adverse event (n=2), withdrawal of consent (n=1) or the physician’s decision (n=1). There 
was little pulmonary toxicity except that the lung function of 5 patients decreased, but they 
did not stop their treatment. Among patients, 24 were evaluable, including 6 (25%) with a 
partial response and 1 (4%) with a complete response. The remaining 17 patients included 
13 (54%) whose disease was stable and 4 (17%) whose disease progressed. Response rate 
was poorer than expected by the authors (at least 9 responding patients). The median 
overall survival time was 14.4 months for those given the level 1 dose and 19.5 months for 
those given the level 2 dose with no statistical difference. The median overall survival time 
was longer than is usually observed in clinical trials of lung cancer treatment. This 
discrepancy may be due to bias associated with the selection of the patients or because 
inhaled doxorubicin plus platinum chemotherapy really had some effect. A phase III study 
is expected to determine which of these hypotheses is correct. 
5.1.3 Campthotecin 
Vershraegen et al. examined the feasibility of using aerosolised liposomal 9-nitro-20(S)-
camptothecin (L9-NC) (Verschraegen et al., 2000). They treated 6 patients with primary or 
secondary lung tumours who had not responded to previous treatment with L9-NC for 5 
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days a week every 3 weeks. The histology of the lung tumours was not specified, neither 
were any details about the nebulisation procedure given, except that an air flow of 10 liters 
per minute was used to generate the aerosol. No toxicity up to grade 2 was observed. The 
maximum drug concentration was seen 2 hours at the end of the aerosolisation, which 
rapidly decreased. The disease of two patients stabilized. 
The same group then carried out a phase I study with nebulised L9-NC to determine the 
dose-limiting toxicity (Verschraegen et al., 2004). L9-NC was aerosolised with a pneumatic 
nebuliser with an air flow of 10 liters per minute and a mouth breathing-only face mask. 
Patients were treated for 5 days a week as above. The dose was increased by reducing the 
interval between treatments or increasing the concentration of L9-NC. The patients were 
premedicated with an inhaled bronchodilatator and steroids after one of them developed a 
grade 2 bronchial irritation. The starting dose was 6.7 µg/kg. All 25 patients completed the 
protocol except one who could not undergo nebulisation because of claustrophobia. The 26.6 
µg/kg dose was poorly tolerated, with pharyngeal mucositis. The 20.0 µg/kg dose 2 
patients to develop grade 3 asthenia but the 13.3 µg/kg treatment was well tolerated. There 
were mild side effects, such as a cough in 67% of patients, bronchial irritation in 46%, sore 
throat in 33%, nausea in 62%, vomiting in 33%, fatigue in 50%, anemia and neutropenia in 
29%, and skin rash around the face mask in 21%. There was a 20% decrease in FEV1 during 
treatment which rapidly returned to baseline. Other lung function parameters were stable. 
The blood plasma L9-NC concentration peaked 2 hours after nebulisation, which was 
followed by a sustained decrease. The blood concentrations were similar to those obtained 
after oral administration, without any haematological toxicity. The responses to treatment 
were reported, but a phase I study is not designed to do so. Two patients had a partial 
remission, with endometrial carcinoma metastatic to the lungs only, but they suffered a 
relapse within 8 and 3 years respectively. One of these patients had a partial response of 
hepatic metastasis. The disease of the patients with lung tumours (3 of 6) was stabilized. 
Thus, nebulised L9-NC seems to be promising for treating pulmonary metastases rather 
than primary lung tumours. The recommended phase II study dose was 13.3 µg/kg 5 days a 
week every week. 
5.1.4 5-Fluorouracile 
Tastumura et al. were the first to report chemotherapeutic nebulisation for cancer patients 
(Tatsumura et al., 1983).  They treated six patients with lung cancer with 5-FU aerosolised 
with an ultrasonic nebuliser. Two of them had complete responses and two others partial 
responses. Only traces of 5-FU were detected in the blood. These encouraging results led to 
another clinical trial to assess nebulised 5-FU for treating primary lung tumour patients 
(Tatsumura et al., 1993). A first group of 19 patients with resectable lung cancer was given 
nebulised 5-FU, 2 hours before surgery to determine the 5-FU concentrations in excised lung 
tissue. The 5-FU concentration in the tumour tissue was 5-15 times higher than in the normal 
lung tissue (p<0.05). The 5-FU concentrations were higher in proximal tissue and regional 
lymph nodes than in the remaining tissue. No drug was detected in blood samples. A 
second group of ten patients with unresectable lung cancer (6 squamous cell carcinomas and 
4 adenocarcinomas) were given inhaled 5-FU twice a day for 3 days per week to evaluate 
their response to treatment. Of these, 6 had objective responses, including two complete 
responses and four partial responses. The disease of the remaining four patients was 
unchanged and 3 of them died of their disease. No toxicity was detected. Despite these 
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promising results, no clinical trial to assess the efficacy of inhaled 5-FU has been published, 
probably because i.v. injected 5-FU is not indicated for treating lung cancer. 
5.1.5 Non-steroidal anti-inflammatory drugs 
To the best of our knowledge, no clinical trial has assessed the efficacy of inhaled non-
steroidal anti-inflammatory drugs for treating cancer patients, although aerosolised 
celecoxib plus i.v. chemotherapeutic agents showed good results in preclinical studies. 
5.2 Aerosolisation of anticancer drugs in pulmonary metastases 
5.2.1 Interleukin-2 
The characteristics of clinical trials of inhaled interleukin-2 are summarized in Table 1. 
Interleukin-2 (Il-2) was initially administered intravenously to treat patients with 
melanomas and renal cell carcinoma with some good results (Rosenberg et al., 1994). 
However, severe toxicity limits its intravenous administration (Mitani et al., 1992). It was 
logical, therefore, to evaluate IL-2 delivered via the airways. It was the first drug delivered 
via this route to be tested in a clinical trial for treating lung metastases (Huland et al., 1994). 
Patients with pulmonary metastases of renal-cell carcinoma were given IL-2 together with 
low doses of IL-2 injected subcutaneously (10% of total IL-2 dose) and systemic 
subcutaneous interferon alpha (IFN alpha). Toxicity was low, grade II toxicity occurred in 
only one patient who suffered bronchospasms. The pulmonary metastases did not increase 
during treatment. One of the 15 patients treated showed a complete response, 8 had partial 
responses, and the lung disease of 6 was stable. Surprisingly, 3 of 7 patients had partial 
responses of non-pulmonary metastases and one was stabilized. The mean survival time 
was 19.1 months, whereas the mean survival time of patients with renal carcinoma 
metastases is usually 9.9 months.  
Inhaled natural IL-2 alone was also assessed in a phase I study on 16 patients, including 14 
with pulmonary metastases of renal cell carcinomas and 2 non small cell lung cancers 
(Lorenz et al., 1996). Treatment was initially delivered once a day and progressively 
increased to reach 5 times a day over 43 days. Aerosol particles had an MMAD of about 2.3 
µm. Treatment was relatively safe. Coughs were one of the most common adverse side 
effects and one patient fractured a rib, but no systemic toxicity was reported. The effect on 
lung function was mild to moderate. IL-2 was not detected in the blood with the low dose, 
but increased within 2 to 6 hours with the high dose. The pulmonary metastases of 3 
patients went into complete regression, but 2 of them died from non-pulmonary metastases. 
The safety and efficacy of inhaled IL-2 was evaluated in a study on 7 patients with 
pulmonary metastases of renal carcinomas (Nakamoto et al., 1997). The drug was 
aerosolised with an ultrasonic nebuliser and delivered over 10 minutes for 5 days a week. 
Treatment was associated with subcutaneous injections of interferon alpha. One patient 
stopped the treatment before three months because his overall health deteriorated. The 
disease of two of the remaining 6 became stable, 3 had partial responses and the disease of 
one patient with cystic renal disease progressed. One patient developed severe toxicity, 
pulmonary fibrosis appearing within 4 months and treatment was stopped. His metastases 
grew dramatically and he died 6 months after treatment cessation. 
The safety of inhaled IL-2 led Huland et al. to perform a clinical trial on a large cohort 
(Huland et al., 1999a). The 116 patients with pulmonary metastases of renal carcinoma 
included this 6-year study were given high doses of aerosolised IL-2, either alone (11%), 
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with a low dose given subcutaneously IL-2 (33%), or with low-dose systemic IL-2 and 
interferon-alpha (56%). The overall response rate was 16% for IL-2 alone, 49% for IL-2 plus 
subcutaneous (s.c.) IL-2, and 35% for IL-2 plus s.c. IL-2 and interferon. The median overall 
response was 9.6 months. The pulmonary metastases of 15% of patients progressed and 
those of 55% were stabilized. The authors identified risk factors of poor response in patients 
treated with inhaled IL-2 (Huland et al., 1999b). Of the 116 patients given inhaled IL-2 
(natural or recombinant), 86 had a poor response and at least one of the following risk 
factors: 1 metastatic location (86%), interval between diagnosis and treatment of <12 months 
(62%), weight loss prior to therapy (41%), and ECOG (Eastern Cooperative Oncology 
Group) performance status ≥2 (13%). However, the response rate, including long-term 
stabilization, was 27 to 57% in patients with these risk factors. Inhaled IL-2 should be 
proposed for all renal cancer patients with pulmonary metastases. However, patient with 
multiple nodules and who are tired may have reduced lung deposition of inhaled treatment. 
Another clinical trial was conducted on 40 patients with progressive pulmonary metastases 
of a renal cell carcinoma. They were treated with inhaled IL-2 3 times a day for a total dose 
of 18 million units (MU) plus a low dose of systemic IL-2 (Merimsky et al., 2004). The dose 
was reduced for one patient because of a cough and dyspnea. The dose was increased to 36 
MU for seven patients whose disease progressed. The response rate was poorer than in 
previous studies supervised by Huland et al. Only one of the 40 patients had a partial 
response, but the disease of 22 patients was stabilized. The median time to progression was 
8.7 months. Toxicity was low including cough, weakness, dyspnea, fever and abdominal 
pain. The efficacy and safety of inhaled IL-2 were also assessed in a retrospective study on 
51 patients with pulmonary metastases of renal cell carcinoma (Esteban-González et al., 
2007). The patients were given 3 cycles of 36 MU per day for 5 days per week for 12 weeks. 
Toxicity was low, always grade 1 or 2. Cough and fatigue were the most common problems. 
The overall objective response rate was 13.7%. The median progression-free survival time 
was 8.6 months and the overall survival time was 23 months. Inhaled IL-2 seemed to have 
an effect but it was not compared to a control group. A retrospective study compared 94 
patients with metastases of renal carcinoma treated with inhaled IL-2 to 103 patients treated 
with systemic IL-2 (Huland et al., 2003). The toxicity in the two groups was radically 
different. Cough was observed in the inhaled IL-2 group and fever, fatigue, skin lesion in 
systemic IL-2 group. The 1-, 2- and 3-year survival rates were estimated to be 47%, 28% and 
23% for inhaled IL-2 and 26%, 10% and 1% for the systemic IL-2 group. The hazard ratio for 
inhaled IL-2 was 0.435. The death risk of patients treated with inhaled IL-2 was decreased by 
44%. 
The largest clinical trial with a drug delivered via the pulmonary route to treat lung cancer 
was the study conducting by Atzpodien et al. (Atzpodien et al., 2006). The 379 patients with 
metastases of renal cell carcinoma were randomly assigned to group I (143 patients) or 
group II (236 patients). The group I patients in arm A were given subcutaneous IL-2, 
subcutaneous interferon-α plus 13-cis-retinoic acid; those in arm B were given the same 
treatment as arm A plus inhaled IL-2. The patients in group II were assigned to arm C (arm 
A plus intraveinous 5-FU) or arm D (arm A plus oral capecitabine). The 13-cis-retinoic acid 
used in this study is a regulator of cell differentiation that has been reported to enhance the 
antitumor effect of IL-2/IFN-α on renal cell carcinoma metastases (Atzpodien et al, 1995). 
Patients with pulmonary metastases were preferentially assigned to group I. Arm B patients 
were given systemic IL-2 and IFN- plus inhaled IL-2 on days 1 to 5 of weeks 2 and 3 and 
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 Drugs Patients Toxicity Response 
rate 
Outcome 
Huland et 
al. 1994 
Inhaled IL2 + 
low dose 
systemic IL-2 
+ systemic IFN 
15 patients 
with RCC 
Grade 2 (7%) 
Bronchospasm in 
1 patient  
1 CR 
8 PR 
6 SD 
OS= 19,1 months 
Lorenz et 
al. 1996 
Inhaled IL-2 
alone 
14 patients 
with RCC 
2 patients 
with 
NSCLC 
Cough 
Mild to moderate 
decrement of 
lung function 
1 CR 
1 PR 
6 SD 
NA 
 
Nakamoto 
et al. 1997 
Inhaled IL-2 
and s.c. IFN 
7 patients 
with RCC 
1 patient with 
pulmonary 
fibrosis 
3 PR 
2 SD 
 
NA 
 
Huland et 
al. 1999 
Inhaled IL-2 
either alone or 
with low dose 
s.c. IL-2 or 
with low-dose 
s.c. IL-2 and 
IFN 
116 patients 
with RCC 
Grade 3 (16%) CR/PR/SD:  
-16% IL-2  
-49% with 
inhaled and 
s.c. IL-2 
-35% with 
tritherapy 
PFS= 9.6 months 
 
OS= 11.8 months 
Huland et 
al. 2003 
Inhaled IL-2 vs 
systemic IL-2 
94 patients 
with 
inhaled IL-2 
and 103 
patients 
with 
systemic IL-
2 
cough CR/PR/SD: 
-45% inhaled 
IL-2 
-35% systemic 
IL-2 
Inhaled IL-2 
1-year survival : 47% 
2- year survival: 28% 
3-year survival: 23% 
Systemic IL-2 
1-year survival : 26% 
2- year survival: 10% 
3-year survival: 1% 
Merimsky 
et al. 2003 
Inhaled IL-2 
and low dose 
systemic IL-2 
40 patients 
with RCC 
cough, weakness, 
dyspnea, fever 
and abdominal 
pain 
1 PR 
22 SD 
PFS=8.7 months 
 
Atzpodien 
et al. 2006 
Arm A : and 
systemic IL-2 
and 13-cis-
retinoic acid 
Arm B: Arm A 
and Inhaled 
IL-2 
379 patients 
with RCC 
Equal toxicity for 
each arm (more 
than 5% of grade 
III/IV toxicity). 
No respiratory 
toxicity was 
reported in arm B 
Arm A: 
12% CR 
19% PR 
26% SD 
Arm B: 
10% CR 
19% PR 
36% SD 
 
Arm A : PFS=5 
months 
OS= 22 months 
Arm B : PFS= 4 
months 
OS= 18 months 
Esteban-
González 
et al. 2007 
Inhaled IL-2 51 patients 
with RCC 
Grade 1 and 2 
exclusively 
CR/PR/SD: 
13.7% 
PFS=8.6 months 
OS=23 months 
Table 1. Main characteristics of clinical trials assessing inhaled interleukin-2. PFS: 
progression-free survival, OS: overall survival, CR: complete response, PR: partial response, 
SD: stable disease. 
www.intechopen.com
 The Airways: A Promising Route for the Pulmonary Delivery of Anticancer Agents 
 
69 
weeks 5 to 8 with a pneumatic nebuliser producing 3 µm particles. A cycle was considered 
to be 8 weeks and patients were given 3 courses. Sixty patients (15.8%) (arm A: 14%; arm B: 
9.2%; arm C: 21.6%; arm D: 15%) did not complete treatment due to disease progression 
before the first evaluation (2.9%), intolerance (8.7%), death during therapy (1.6%), patients’ 
wish (2.1%), and non-compliance (0.5%). The endpoints were overall survival, progression-
free survival and objective response to treatment. In arm A, 8 patients (10%) had a complete 
response and 15 patients (19%) had a partial response, 28 (36%) had stable disease and the 
disease of 27 (35%) progressed despite treatment. The overall objective response rate was 
29% (95% CI 19, 40). In arm B, 8 patients (12%) had a complete response, 12 (19%) a partial 
response, 17 (26%) had stable disease, and the disease of 28 (43%) progressed. The overall 
objective response rate was 31% (95% CI 20, 44). The patients in arms C and D had similar 
results. Progression-free survival was 5 months in arm A, 4 months in arm B, 0 month in 
arm C and 4 months in arm D with no statistical difference between them. The overall 
survival time was 22 months in arm A, 18 months in arm B, 18 months in arm C, and 16 
months in arm D with no statistical difference. All four treatments were moderately well 
tolerated with equal toxicity for each arm (more than 5% of grade III/IV toxicity). No 
respiratory toxicity was reported in arm B with inhaled IL-2. The treatment based on s.c. IL-
2, s.c. IFN and oral 13-cis-retinoic acid was probably too toxic for the advantages of inhaled 
IL-2 to be detected. Clinical trials associating an oral tyrosine kinase inhibitor like sorafenib 
with inhaled IL-2 might be interesting. A study on 10 patients reported asthma in response 
to inhaled IL-2 (Loppow et al., 2007), but only one patient had to stop treatment. 
Skubitz et al. demonstrated that interleukin-2 encapsulated in liposomes could be delivered 
by aerosol to patients with pulmonary metastases (Skubitz et al., 2000). They gave 9 patients 
liposomes containing IL-2 or placebo with a jet nebuliser and a standard compressor. The 
IL-2 treatment was inhaled for about 20 minutes 3 times a day. No significant toxicity was 
observed and inhalation was well tolerated. Further studies are expected. However, it is 
hard to see the clinical advantage of inhaled liposomal IL-2 considering the impressive 
results of the free form, unless it could improve IL-2 resident time in the airways, so 
reducing the number of treatments.  
5.2.2 Monoclonal antibodies and tyrosine kinase inhibitor 
To the best of our knowledge, no clinical trials have tested inhaled antibodies or tyrosine 
kinase inhibitors for treating lung cancer patients. 
5.2.3 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) 
GM-CSF was first assessed in a dose escalation study on 7 patients with pulmonary 
metastases (2 patients with osteosarcoma, 2 with melanoma, 1 with leiomyosarcoma, 1 with 
renal cell carcinoma and 1 with Ewing’s sarcoma) (Anderson et al., 1999). They were given 
GM-CSF aerosolised with a pneumatic nebuliser. One was not treated due to rapid disease 
progression. The remaining 6 patients were given the drug twice a day for one week, and 
treatment was stopped for one week. The starting dose was 60 µg. The dose was increased 
to determine dose-limiting toxicity. Those given the high dose showed a minor increase in 
their white blood cell count that was not statistically different from their white blood cell 
count before treatment. Lung function was stable except in one patient with osteosarcoma 
whose FVC increased. No toxicity was described. Although it was a dose escalation study, 
treatment response was reported. Of the six patients who completed study, the disease of 4 
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stabilized for 9 months, 1 had a partial response and 1 had a complete response (patient 
with Ewing’s sarcoma). The authors suggest that the low GM-CSF concentration into the 
bloodstream after airways delivery may be attributed to GM-CSF sequestration into the 
lungs by immune effectors. This therapy was given to 45 other patients (40 with pulmonary 
metastases) to better evaluate the toxicity of inhaled GM-CSF (Rao et al., 2003). They were 
given nebulised GM-CSF (250 µg) twice a day for 1 week followed by a 1 week rest. 
Moderate toxicity was observed in 18 patients. The disease of 24 patients was stabilized or 
partially responded (8 of 13 with a sarcoma, 6 of 14 with melanoma, and 5 of 12 with renal 
cell carcinoma). The efficacy of aerosolised GM-CSF might be due to stimulation of an 
antitumor immune response because one patient with pulmonary metastases of melanoma 
had a 10-fold increase in specific cytotoxic T lymphocytes resulting in a partial response. 
The authors suggested that there was a dose-dependent response to the treatment and 
conducted a third dose escalation study with doses higher than in previous trials (Markovic 
et al., 2008). Only patients with pulmonary metastases of melanomas were included because 
the authors postulated that there could be an antitumor auto-immunization against the 
melanoma, as suggested by increase in melanoma-specific lymphocyte T in previous study. 
Aerosolised GM-CSF was delivered with a pneumatic nebuliser twice daily on days 1 to 7 
and 15 to 21 in a 28-day cycle. Doses ranged from 500 to 2000 µg. The author considered 
aerosolised GM-CSF to be well tolerated.because only 3 of the 40 patients had severe 
toxicity, including grade 4 dyspnea in 1 patient given 2000 µg and 1 patient given 1750 µg, 
and grade 3 fatigue in 1 patient given 1000 µg. There were increases in melanoma-specific 
cytotoxic T lymphocytes in 9 patients (1 given 500 µg, 1 given 750 µg, 2 given 1500 µg, 1 
given 1750 µg, and 4 given 2000 µg). Although the data are descriptive, the authors reported 
that one patient on 2000 µg had a partial response and the disease of 6 became stable.  None 
of the GM-CSF doses used induced antitumor immunity in the majority of patients. Further 
studies are needed to determine the extent of the antitumor immunity induced by 
aersosolised GM-CSF in melanoma. A recent clinical trial treated 43 adults and children 
with lung relapses of osteosarcoma with inhaled GM-CSF. They were given 2 cycles of 
inhaled GM-CSF, then the tumour nodules were surgically removed. The patients were then 
given 12 cycles of inhaled GM-CSF (Arndt et al., 2010). Treatment was given 5 days per 
week every 2 weeks and the dose range was from 250 µg to 1750 µg. The Fas and Fas ligand 
were assayed in the removed nodules to assess the immunomodulatory effect of GM-CSF. 
Nine patients had grade 3 respiratory toxicity, including 5 patients on 1750 µg. Thirty seven 
patients suffered relapses. The median free survival time was 4.3 months and the overall 
survival rates were 63.1% at 2 years and 35.4% at 3 years. GM-CSF was found to have no 
immunomodulatory effect, and this potential property of GM-CSF remains controversial. 
5.3 Aerosols in palliative cancer care 
Breathlessness is a serious problem for cancer patients in palliative care because of the 
discomfort it causes. Drugs are usually given systemically to relieve this discomfort, but this 
is invasive and often requires hospitalization. 
5.3.1 Morphine and other opiod analgesics 
The opiate analgesic morphine is widely used and is given orally, intravenously or 
subcutaneously to cancer patients to relieve pain. The effect of morphine on breathlessness 
was suggested more than 20 years ago (Bruera et al. 1990) and reported in a systematic 
review in 2002 (Jennings et al., 2002). Delivering morphine via the pulmonary route might 
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decrease breathlessness because there are morphine receptors in the lungs. The safety and 
pharmacology of aerosolised-morphine have been evaluated in cancer patients with 
dyspnea. 
5.3.1.1 Safety 
A safety trial conducted on 50 cancer patients with dyspnea revealed no major adverse 
reactions, such as respiratory distress or vomiting (Tanaka et al., 1999). The 20 mg dose of 
morphine was delivered with an ultrasonic nebuliser. Dyspnea was measured using a visual 
analog scale based on the subjective quantification of breathlessness by the patient.  
Nebulised morphine produced a significant 10% decrease in dyspnea.  
5.3.1.2 Pharmacokinetics 
Morphine 6 glycuronide (M6G) is an active metabolite of morphine. The pharmacokinetics 
of inhaled M6G were analysed on 10 healthy volunteers (Penson et al., 2002). M6G was 
delivered as an intravenous bolus (2 mg), subcutaneously (2 mg) or by inhalation (4 mg). 
The bioavailability of M6G was 102% after s.c. delivery and 6% after airways delivery 
compared to intravenous route. The peak of M6G in the blood appeared from 30 minutes to 
2 h after s.c. delivery and from 1.2 to 8 hours after airways delivery. A previous study found 
that the bioavailability of nebulised morphine was 17%, suggesting that little passed into the 
blood (Chrubasik et al., 1988). A recent study by Krajnik et al. compared two methods of 
morphine nebulisation (Krajnik et al, 2009). Morphine, at a dose of 5 mg, was given to 10 
breathless cancer patients with a nebuliser producing 2-5 µm or 0.5-2 µm particle droplets. 
The nebuliser producing the larger particles resulted in more metabolite being released into 
the blood, but a longer procedure was needed to deliver the 5 mg dose and the maximum 
plasma concentration of the metabolite occurred later. No toxicity was observed. A clinical 
trial comparing the efficacy of the two devices is required. 
The published pharmacokinetic studies on morphine and its metabolite suggest that little 
passes into the blood. 
5.3.1.3 Efficacy 
5.3.1.3.1 Uncontrolled trials 
The safety profile and poor passage into the blood led to clinical trials to analyse the efficacy 
of inhaled morphine.  Quigley el al. treated 9 cancer patients suffering from breathlessness 
with M6G in a phase I/II study (Quigley et al., 2002). They were given a single dose of 5 mg, 
10 mg, or 20 mg M6G. Treatment was well tolerated. Pharmacokinetic analysis showed a 
blood peak at 2 hours for all doses with a blood concentration proportional to the dose. The 
patient status based on visual analog scale of breathlessness and dyspnea (Borg score) was 
significantly improved, with no difference between doses. The inhalation of a derivative of 
morphine, hydromorphone, was also evaluated in cancer patients (Coyne et al., 2002). These 
32 breathless patients inhaled hydromorphone and were assessed at baseline, 5 minutes and 
60 minutes after nebulisation. The patients assessed their change as the same, worse, or 
improved. Most of them (26; 81%) reported improved breathing and 6 (9%) found no 
change. Oxygen saturation was improved from 94.6% at baseline to 96.8% at 5 minutes and 
96.7% at 60 minutes. 
5.3.1.3.2 Controlled trials 
The above results should be interpreted with caution because there was no control group 
(aerosolised placebo or i.v. opioids). A few years ago we performed a trial with inhaled 
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morphine (20 mg) or normal saline in 10 cancer patients (Grimbert et al., 2004). The patients 
were given both treatments over 48 hours, separated by a wash-out period. Dyspnea, 
respiratory rate and oxygen saturation were assessed on a visual analog scale before and 
after treatment. The scores improved after both treatments, but respiratory rate and oxygen 
saturation did not change, indicating no specific drug response. We postulated that the 
improved comfort was due to a nebulisation-dependent humidification of the airways or a 
placebo response. Our results differ from those of Coyne et al., who described an improved 
perception of breathing, respiratory rate and oxygen saturation following treatment with 
nebulised fentanyl citrate (Coyne et al., 2002). This difference may be due to a great 
variation in the oxygen saturation measured and the subjective dyspnea measurement.  
Bruera et al. compared the effects of nebulised morphine and subcutaneous morphine on 11 
cancer patients suffering from breathlessness (Bruera et al., 2005). On day 1 they were given 
nebulised morphine plus a subcutaneous placebo, or nebulised placebo plus subcutaneous 
morphine. The treatments were reversed on day 2. Both treatments were very well tolerated. 
The score of the group given morphine subcutaneously decreased significantly from 5 to 3 
on a visual analog scale, and that of the nebulised drug group decreased from 4 to 2. 
However, only 11 patients were studied and the visual analog scale fluctuated during the 
subcutaneous morphine treatment. A more recent study compared the effects of nebulised 
hydromorphone, intravenous hydromorphone, and nebulised normal saline on twenty 
patients (Charles et al., 2008). Patients needing treatment for breathlessness were randomly 
given 5 mg of nebulised hydromorphone, a systemic breakthrough dose of hydromorphone, 
or 3 ml of nebulised saline on three different occasions. A placebo given by another route 
was administrated. The primary goal of a decrease in the visual analog scale within 10 
minutes was not reached. There were significant decreases over a longer period but no 
difference between treatments. 
Thus, these studies with a placebo control group have not demonstrated any difference 
between nebulised opioid and placebo. However both treatments seemed to significantly 
improve the patients’ perception of breathing, which may be attributed to a placebo effect or 
improved airway humidity. 
5.3.2 Furosemide 
Inhaled furosemide was used with some success to treat breathlessness asthma patients and 
healthy volunteers whose breathlessness was induced (Bianco et al., 1989, Nishino et al., 
2000).  
This finding led to inhaled furosemide being evaluated in cancer patients. A group of three 
cancer patients reported improved dyspnea when given nebulised furosemide (20 mg) 
(Shimoyama et al., 2002). Nebulisation of a bronchodilator before giving inhaled furosemide 
had no effect and the authors excluded a placebo effect. A study on 15 cancer patients 
suffering from breathlessness assessed the effect of ultrasonically nebulised furosemide (20 
mg) (Kohara et al., 2003). Cancer dyspnea was measured with a brief self-rating scale of 12 
items. Most patients (n=12; 80%) reported significant improvements in their cancer dyspnea 
and anxiety. Their heart rates, respiratory rates and oxygen saturation were not improved. 
The improved dyspnea might have been due to a placebo effect or improved airway 
humidity, as observed in inhaled morphine studies. A controlled trial on 7 cancer patients 
treated with inhaled normal saline or furosemide (20 mg) found that the scores of the visual 
analog scale were better after saline than after furosemide, but without statistical 
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significance (Stone et al., 2002). Another study that included placebo group confirmed that 
inhaled furosemide had little effect on the breathlessness of 15 cancer patients (Wilcock et 
al., 2008). They assessed the patients’ perception of breathing before and 60 minutes after 
treatment; they found no improvement in either group. There were small decreases in FEV1 
and vital capacity after nebulised normal saline but not after nebulised furosemide. 
5.4 Chemoprevention of lung cancer by aerosolisation 
The chemoprevention of lung cancer with aerosolised drugs was first tested in animals. 
Budesonide, an inhaled steroid, inhibited the formation of lung tumour by over 80% 
(Wattenberg et al., 1997). Squamous cell carcinoma in hamsters was reduced by 50% with 
inhaled difluoromethylornitine and 60% with and inhaled 5-FU (Wattenberg et al., 2004). 
The results of clinical trials of the chemopreventive effects of inhaled steroid have been 
equivocal. Lam et al. suggested that budesonide had no effect on bronchial dysplastic 
lesions and did not prevent new lesions forming in 112 smokers (Lam et al., 2004). In 
contrast, fluticasone delivered by aerosol gave promising results, with significantly fewer 
treated patients with increasing numbers of nodules than in the placebo group (Van den 
Berg et al., 2008). A clinical trial in which 11 subjects with lung metaplasia or dysplasia were 
given aerosolized vitamin A found complete or partial responses in 56% of cases (Kohlhäufl 
et al., 2002) 
Further studies are needed to determine whether inhaled steroid and vitamin A really do 
have chemopreventive effects. 
Others aerosolised agents such as pioglitazone (an antidiabetic agent), polyphenons E (a 
mixture of polyphenons) and bexarotene (a retinoid X receptor (RXR) agonist) had 
promising results in animal studies (Fu et al. 2009, 2011, Yan et al., 2007, Zhang et al. 2011). 
6. Perspectives and conclusion 
Most of the preclinical studies have shown that aerosolisation preserves anti-cancer 
properties of a large amount of agents. Administration through the pulmonary route of 
anticancer drugs is well tolerated in animal models. Lung deposition is better following 
airways than systemic delivery. Moreover, blood passage is often lower when anti-cancer 
agents are administered through the airways. To date, the clinical studies of inhaled 
anticancer agents such as cisplatin, campthotecin, 5-fluoro-uracile, have demonstrated the 
safety and the pharmacokinetic advantages of airways administration in cancer patients. 
Moreover, antitumor responses have been observed including complete remission with 
inhaled interleukin-2 in renal cell carcinoma patients or with inhaled doxorubicin in lung 
cancer patients. However, studies were constructed with a small number of patients, the 
histological patterns were mostly heterogeneous with primary and secondary lung tumour 
mixed in the same trial and different devices or dosage were used to evaluate  response to 
the same agent. Thus, it is difficult to bring conclusions on the real efficacy of anti-cancer 
agents administered through the airways, but significant effects are obvious. Despite 
promising results of inhaled anticancer drugs, the aerosol delivery of opioid or furosemide 
in palliative cancer patients was not convincing. Chemoprevention of lung cancer with 
inhaled agents is interesting, but further studies are needed to validate this approach. 
It would be valuable to systematically integrate aerosol metrology and pharmacokinetic 
analysis with preclinical studies in order to improve drug deposition at the target site in the 
respiratory tract, and define the formulation that enables drugs to be retained in the lungs. 
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Standardisation of administration procedures should be considered to enhance 
homogeneity of clinical studies. Data on drug deposition is essential to make comparison 
between patients and drug pharmacokinetics and would be informative in future clinical 
trials. As reported, combined administration of an inhaled anti-cancer agent with drugs 
administered intravenously may be relevant to enhance the anticancer effect. It may also be 
interesting to consider the association of several anticancer agents delivered through the 
pulmonary route. Selting et al. simultaneously delivered in healthy dogs, aerosolised 
cisplatin and gemcitabine via a catheter in right caudal lung lobe without clinical toxicity 
(Selting et al., 2011). Along with conventional agent, biotherapeutics such as IL-2 and GM-
CSF were assessed with promising preclinical and clinical results. Airways may also be 
suited for the local delivery of other biologics, such as monoclonal antibodies (Maillet et al. 
in press). But, researchers now need to evaluate the relative benefits of drug delivery by the 
airways and the systemic route before aerosolised anticancer agents can become a clinical 
reality in oncology. 
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